SCHEMBL580394

SCHEMBL580394

Nc1ccc(Oc2ccccc2-c2ccnc(N)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCOA1 Q15788 1/20 0.54
NCOA3 Q9Y6Q9 1/20 0.54
AURKA O14965 1/20 0.46
HSP90AA1 P07900 1/20 0.46
PRKACA P17612 1/20 0.46
ADORA2A P29274 1/20 0.46
FEN1 P39748 3/20 0.45
ALOX5AP P20292 2/20 0.45
MEN1 O00255 1/20 0.44
APAF1 O14727 1/20 0.44
KMT2A Q03164 1/20 0.44
DYRK1A Q13627 4/20 0.43
GSK3B P49841 3/20 0.43
MAP3K14 Q99558 3/20 0.43
CDK5 Q00535 3/20 0.43
CDK5R1 Q15078 3/20 0.43
CLK1 P49759 1/20 0.43
HTR1A P08908 1/20 0.43
HTR7 P34969 1/20 0.43
HTR2B P41595 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30507528 0.91 HSP90AA1 (0.53) NCOA1NCOA3AURKAHSP90AA1PRKACA
SCHEMBL28501185 0.91 HSP90AA1 (0.53) NCOA1NCOA3AURKAHSP90AA1PRKACA
SCHEMBL4726065 0.86 NCOA1 (0.51) NCOA1NCOA3FEN1ALOX5APMEN1
SCHEMBL580833 0.83 CLK1 (0.49) AURKAHSP90AA1PRKACAADORA2AFEN1
SCHEMBL974439 0.82 IKBKB (0.48) NCOA1NCOA3AURKAIKBKB
SCHEMBL503945 0.81 AURKA (0.51) AURKAHSP90AA1PRKACAADORA2AFEN1
SCHEMBL30507329 0.78 HSP90AA1 (0.60) AURKAHSP90AA1PRKACAADORA2ADYRK1A
SCHEMBL3362587 0.78 HSP90AA1 (0.60) AURKAHSP90AA1PRKACAADORA2ADYRK1A
SCHEMBL29992912 0.77 NCOA1 (0.78) NCOA1NCOA3MEN1APAF1KMT2A
SCHEMBL1143083 0.77 NCOA1 (0.78) NCOA1NCOA3MEN1APAF1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
EP-1984353-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2015-12-30 EP disclosed
EP-1984353-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2015-12-30 EP disclosed
EP-2418209-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-06-25 EP disclosed
EP-2418209-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-06-25 EP disclosed
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2014-03-06 US disclosed
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2014-03-06 US disclosed
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2014-03-06 US disclosed
US-7560551-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-07-14 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
EP-1984353-A1 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2008-10-29 EP disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
WO-2007087276-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2007-08-02 WO disclosed
WO-2007087276-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, AURKB NCOA1 1990/4885NCOA3 2248/4885AURKA 2/4885
US-20070185111-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 NCOA1 1169/4885NCOA3 1866/4885AURKA 2/4885
US-20090163501-A1 Aurora kinase modulators and method of use AURKC, AURKA, AURKB NCOA1 1990/4885NCOA3 2248/4885AURKA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.